Table 2.
Patient’s characteristics
| All N=619 | CFR>2.5 N=365 | CFR≤2.5 N=246 | Missing | P-value | |
|---|---|---|---|---|---|
| Age median (IQR) | 69.0 (64.9–73.3) | 67.7 (63.8–72.0) | 69.7 (65.5–74.6) | 9 | 0.999 |
| Female gender n (%) | 114 (18.4) | 58 (15,9) | 56 (22.8) | 1 | 0.024 |
| BMI mean (± SD) | 27.3 (±3.91) | 27.5 (±3.91) | 26.97 (±3.899) | ||
| Tobacco use n (%) | 8 | 0.258 | |||
| Current smoker n (%) | 68 (11.0) | 38 (10.4) | 30 (12.2) | ||
| Previous smoker n (%) | 331 (50.0) | 191 (52.0) | 140 (56.9) | ||
| Non smoker n (%) | 212 (32.4) | 136 (37.3) | 76 (30.9) | ||
| Diabetes mellitus n (%) | 138 (22.3) | 75 (20.5) | 63 (25.6) | 0.142 | |
| Hypertension n (%) | 414 (66.9) | 238 (65.2) | 176 (71.5) | 0.100 | |
| Hyperlipidemia n (%) | 245 (39.5) | 158 (43.3) | 87 ((35.4) | 0.050 | |
| Renal dysfunction n (%) | 30 (4.8) | 18 (4.9) | 12 (4.9) | 0.976 | |
| Previous stroke n (%) | 32 (5.2) | 15 (4.10) | 17 (6.9) | 0.127 | |
| Previous PCI n (%) | 589 (95.2) | 354 (97.0) | 235 (95.6) | 0.343 | |
| Previous CABG n (%) | 51 (8.2) | 28 (7.7) | 23 (9.3) | 0.462 | |
| Previous PAD n (%) | 17 (2.7) | 9 (2.5) | 8 (3.3) | 0.562 | |
| COPD n (%) | 23 (3.7) | 12 (3.3) | 11 (4.5) | 0.451 | |
| Multivessel disease n (%) | 285 (46.0) | 183 (50.1) | 102 (41.4) | 0.063 | |
| Additional MI n (%) | 76 (12.3) | 53 (14.5) | 23 (9.3) | 0.071 | |
| Incomplete revascularization n (%) | 147 (23.7) | 71 (19.4) | 76 (30.9) | 0.001 | |
| Angina pectoris n (%) | 72 (11.6) | 44 (12.1) | 28 (11.4) | 0.800 | |
| NYHA | 0.889 | ||||
| Class I n (%) | 571 (92.2) | 343 (94.0) | 228 (92.7) | ||
| Class II n (%) | 40 (6.5) | 22 (6.0) | 18 (7.3) | ||
| Medication | |||||
| ASA n (%) | 576 (93.1) | 345 (94.5) | 231 (93.9) | 0.500 | |
| P2Y12 n (%) | 103 (16.6) | 75 (20.5) | 28 (11.4) | 0.004 | |
| No P2Y12 | 516 (83.4) | 298 (81.6) | 218 (88.6) | ||
| Prasugrel | 1 (0.2) | 0 (0) | 1 (0.4) | ||
| Clopidogrel | 23 (3.7) | 13 (3.6) | 10 (4.1) | ||
| Ticagrelor | 79 (12.8) | 62 (17.0) | 17 (6.9) | ||
| Statins n (%) | 557 (90.0) | 333 (91.5) | 224 (91.1) | 0.470 | |
| ACEI/ARB n (%) | 511 (82.6) | 295 (80.8) | 216 (87.8) | 0.005 | |
| Beta-receptor blocker n (%) | 500 (80.8) | 300 (82.2) | 200 (81.3) | 0.788 | |
| Diuretics n (%) | 114 (18.4) | 61 (16.7) | 53 (21.5) | 0.103 | |
| Insulin n (%) | 34 (5.5) | 18 (10.4) | 16 (6.5) | 0.370 | |
| Oral antidiabetics n (%) | 103 (16.6) | 55 (15.1) | 48 (7.8) | 0.119 | |
| Heart rate mean (±SD) | 60.5 (9.2) | 59.1 (8.9) | 62.5 (9.2) | <0.001 | |
| CFR LAD mean (±SD) | 2.74 (±0.79) | 3.24 (±0.58) | 2.04 (±0.42) | <0.001 |
Abbreviations: BMI, body mass index; PCI, percutaneous coronary intervention; CABG, coronary artery by-pass surgeryl; COPD, chronic obstructive pulmonary disease; MI, myocardial infarction; NYHA, New York Heart Association; ASA, acetylsalicylic acid; P2Y12, inhibitor of P2Y12 receptors; ACE, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor inhibitor; CFR, coronary flow reserve; LAD, left anterior descending artery.